Last reviewed · How we verify
Etofen (ETOFENAMATE)
Etofen (generic name: ETOFENAMATE) is a etofenamate drug. It is currently in Phase 2 development for Osteoarthritis.
Etofenamate works by blocking the production of prostaglandins, which are chemicals that cause pain and inflammation.
Etofenamate is a small molecule drug in the etofenamate class, used to treat osteoarthritis. Its exact target is unknown, but it is believed to work by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. Etofenamate is not currently listed as an off-patent medication, but its commercial status is unclear. As a result, its availability and pricing may vary. Further research is needed to fully understand its pharmacokinetics and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ETOFENAMATE |
|---|---|
| Drug class | etofenamate |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Imagine your body has a factory that produces chemicals called prostaglandins, which are like messengers that tell your brain that you're in pain. Etofenamate is like a key that locks the factory door, stopping the production of these pain-causing chemicals. This helps to reduce pain and inflammation in people with osteoarthritis.
Approved indications
- Osteoarthritis
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etofen CI brief — competitive landscape report
- Etofen updates RSS · CI watch RSS
Frequently asked questions about Etofen
What is Etofen?
How does Etofen work?
What is Etofen used for?
What is the generic name of Etofen?
What drug class is Etofen in?
What development phase is Etofen in?
Related
- Drug class: All etofenamate drugs
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Osteoarthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing